Tectonic Therapeutic reported positive Phase 1b trial results for TX45, showing improved hemodynamics in PH-HFpEF patients without serious adverse events. Despite the positive results, the company ...
WATERTOWN, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic ...
Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and impact on renal plasma flow ( ...
TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial Results to be presented at the ...
TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”) TX45 was well tolerated ...
Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David Risinger called in his report “the most impressive hemodynamic results we ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”), supporting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results